Carlos de Andrea

2.7k total citations · 2 hit papers
23 papers, 1.1k citations indexed

About

Carlos de Andrea is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Carlos de Andrea has authored 23 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 9 papers in Immunology. Recurrent topics in Carlos de Andrea's work include Cancer Immunotherapy and Biomarkers (8 papers), Immunotherapy and Immune Responses (7 papers) and Lung Cancer Treatments and Mutations (6 papers). Carlos de Andrea is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), Immunotherapy and Immune Responses (7 papers) and Lung Cancer Treatments and Mutations (6 papers). Carlos de Andrea collaborates with scholars based in Spain, United States and United Kingdom. Carlos de Andrea's co-authors include Pedro Berraondo, Ignacio Melero, José Luis Perez‐Gracia, María E. Rodríguez-Ruiz, Miguel F. Sanmamed, Ascensión López-Dı́az de Cerio, Alfonso Gúrpide, Susana Inogés, Sonia Tejada and Jaime Gállego Pérez‐Larraya and has published in prestigious journals such as Nature, Nature Medicine and SHILAP Revista de lepidopterología.

In The Last Decade

Carlos de Andrea

23 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma

2019 449 citations Kurt A. Schalper, María E. Rodríguez-Ruiz et al. Nature Medicine profile →
Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy

2019 323 citations Elísabeth Pérez-Ruiz, Luna Minute et al. Nature profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Carlos de Andrea Spain	10	658	519	303	234	231	23	1.1k
Soo Jeong Nam South Korea	21	795 1.2×	475 0.9×	179 0.6×	270 1.2×	489 2.1×	49	1.5k
Brian Ahn United States	12	520 0.8×	734 1.4×	499 1.6×	263 1.1×	280 1.2×	15	1.4k
Martin Kornacker Germany	20	564 0.9×	399 0.8×	299 1.0×	160 0.7×	380 1.6×	59	1.3k
Orsolya Rajky Austria	9	786 1.2×	444 0.9×	661 2.2×	478 2.0×	199 0.9×	14	1.3k
Jillian Phallen United States	13	494 0.8×	372 0.7×	282 0.9×	242 1.0×	315 1.4×	31	1.1k
An Coosemans Belgium	21	523 0.8×	545 1.1×	87 0.3×	283 1.2×	409 1.8×	76	1.6k
Fotis Asimakopoulos United States	20	557 0.8×	333 0.6×	105 0.3×	92 0.4×	538 2.3×	40	1.3k
Jie Qing Chen United States	8	637 1.0×	481 0.9×	305 1.0×	158 0.7×	257 1.1×	15	994
Thomas Hawthorne United States	20	660 1.0×	421 0.8×	145 0.5×	243 1.0×	274 1.2×	40	1.2k
Yong‐Oon Ahn South Korea	21	676 1.0×	646 1.2×	128 0.4×	296 1.3×	336 1.5×	45	1.4k

Countries citing papers authored by Carlos de Andrea

Since Specialization

Citations

This map shows the geographic impact of Carlos de Andrea's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carlos de Andrea with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carlos de Andrea more than expected).

Fields of papers citing papers by Carlos de Andrea

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carlos de Andrea. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carlos de Andrea. The network helps show where Carlos de Andrea may publish in the future.

Co-authorship network of co-authors of Carlos de Andrea

This figure shows the co-authorship network connecting the top 25 collaborators of Carlos de Andrea. A scholar is included among the top collaborators of Carlos de Andrea based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carlos de Andrea. Carlos de Andrea is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Eguren‐Santamaría, Iñaki, Inmaculada Rodríguez, Arantza Azpilikueta, et al.. (2024). Short-term cultured tumor fragments to study immunotherapy combinations based on CD137 (4-1BB) agonism. OncoImmunology. 13(1). 2373519–2373519. 2 indexed citations

Solórzano, José Luis, Edwin R. Parra, Luisa M. Solis, et al.. (2024). Multiplex spatial analysis reveals increased CD137 expression and m-MDSC neighboring tumor cells in refractory classical Hodgkin Lymphoma. OncoImmunology. 13(1). 2388304–2388304. 1 indexed citations

Glez‐Vaz, Javier, Arantza Azpilikueta, María C. Ochoa, et al.. (2023). CD137 (4-1BB) requires physically associated cIAPs for signal transduction and antitumor effects. Science Advances. 9(33). eadf6692–eadf6692. 6 indexed citations

López‐Gutiérrez, Juan Carlos, et al.. (2023). Alpelisib decreases nevocytes of congenital melanocytic nevi. Journal of the European Academy of Dermatology and Venereology. 38(6). 1147–1151. 2 indexed citations

Lozano, María D., et al.. (2023). Immunotherapy and lung cytopathology: Overview and possibilities. Cytopathology. 35(2). 213–217. 3 indexed citations

Teijeira, Álvaro, Saray Garasa, Carlos Luri‐Rey, et al.. (2022). Depletion of Conventional Type-1 Dendritic Cells in Established Tumors Suppresses Immunotherapy Efficacy. Cancer Research. 82(23). 4373–4385. 22 indexed citations

Díaz‐Lagares, Ángel, Juan Díaz‐Martín, Carlos de Andrea, et al.. (2022). Integrating digital pathology with transcriptomic and epigenomic tools for predicting metastatic uterine tumor aggressiveness. Frontiers in Cell and Developmental Biology. 10. 1052098–1052098. 1 indexed citations

Eritja, Núria, Carlos de Andrea, Juan Díaz‐Martín, et al.. (2021). Characterizing the Invasive Tumor Front of Aggressive Uterine Adenocarcinoma and Leiomyosarcoma. Frontiers in Cell and Developmental Biology. 9. 670185–670185. 6 indexed citations

Esteban, Emilio, Francisco Expósito, Guillermo Crespo, et al.. (2021). Circulating Levels of the Interferon-γ-Regulated Chemokines CXCL10/CXCL11, IL-6 and HGF Predict Outcome in Metastatic Renal Cell Carcinoma Patients Treated with Antiangiogenic Therapy. Cancers. 13(11). 2849–2849. 13 indexed citations

10.

García-Moure, Marc, Jaime Gállego Pérez‐Larraya, Ana Patiño‐García, et al.. (2021). EPCT-04. RESULTS OF A PHASE 1 STUDY OF THE ONCOLYTIC ADENOVIRUS DNX-2401 WITH RADIOTHERAPY FOR NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG). Neuro-Oncology. 23(Supplement_1). i47–i47. 1 indexed citations

11.

Schalper, Kurt A., María E. Rodríguez-Ruiz, Ricardo Díez-Valle, et al.. (2019). Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. Nature Medicine. 25(3). 470–476. 449 indexed citations breakdown →

12.

Expósito, Francisco, María Villalba, Miriam Redrado, et al.. (2019). Targeting of TMPRSS4 sensitizes lung cancer cells to chemotherapy by impairing the proliferation machinery. Cancer Letters. 453. 21–33. 27 indexed citations

13.

Redín, Esther, María Villalba, Francisco Expósito, et al.. (2019). P2.03-38 Identification of a Novel Synthetic Lethal Vulnerability in Non-Small Cell Lung Cancer by Co-Targeting TMPRSS4 and DDR1. Journal of Thoracic Oncology. 14(10). S698–S699. 1 indexed citations

14.

Villalba, María, Francisco Expósito, María J. Pajares, et al.. (2019). TMPRSS4: A Novel Tumor Prognostic Indicator for the Stratification of Stage IA Tumors and a Liquid Biopsy Biomarker for NSCLC Patients. Journal of Clinical Medicine. 8(12). 2134–2134. 18 indexed citations

15.

Villalba, María, Esther Redín, Francisco Expósito, et al.. (2019). Identification of a novel synthetic lethal vulnerability in non-small cell lung cancer by co-targeting TMPRSS4 and DDR1. Scientific Reports. 9(1). 15400–15400. 16 indexed citations

16.

Pérez-Ruiz, Elísabeth, Luna Minute, Itziar Otano, et al.. (2019). Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Nature. 569(7756). 428–432. 323 indexed citations breakdown →

17.

Rodríguez-Ruiz, María E., José Luis Perez‐Gracia, Inmaculada Rodríguez, et al.. (2018). Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients. Annals of Oncology. 29(5). 1312–1319. 114 indexed citations

18.

Rodríguez-Ruiz, María E., José Luis Perez‐Gracia, Idoia Rodríguez, et al.. (2017). Combined immunotherapy encompassing intratumoral polyICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients. Annals of Oncology. 28. xi14–xi14. 1 indexed citations

19.

Salinas-Souza, Carolina, Carlos de Andrea, Michel Bihl, et al.. (2015). GNAS mutations are not detected in parosteal and low-grade central osteosarcomas. Modern Pathology. 28(10). 1336–1342. 33 indexed citations

20.

Mohseny, Alexander B., Pieter A. van der Velden, Károly Szuhai, et al.. (2010). Small deletions but not methylation underlie CDKN2A/p16 loss of expression in conventional osteosarcoma. Genes Chromosomes and Cancer. 49(12). 1095–1103. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact